Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xspray Pharma AB ( (SE:XSPRAY) ) has provided an update.
Xspray Pharma AB has re-submitted its application for market approval of Dasynoc® to the FDA, with a PDUFA date set for October 7, 2025. The company is preparing for a potential U.S. launch following a successful FDA Pre-Approval Inspection of its manufacturing lines, indicating a positive step towards market entry.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company focused on developing improved versions of already approved cancer drugs. The company specializes in creating innovative formulations that enhance the bioavailability and therapeutic efficacy of existing medications, with a significant focus on the U.S. market.
Average Trading Volume: 33,741
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.82B
For detailed information about XSPRAY stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money